Legend Biotech Corp ADR
Затворен
СекторЗдравеопазване
29.22 -0.31
Преглед
Промяна на цената на акция
24 ч
Минимум
29
Максимум
30.29
Приходи | -24M -54M |
|---|---|
Продажби | -2.5M 305M |
EPS | -0.15 |
Марж на печалбата | -17.851 |
Служители | 3,100 |
EBITDA | -24M -32M |
Препоръки | Силна покупка |
|---|---|
12-месечна прогноза | +96.42% upside |
Следващи печалби | 10.08.2026 г. |
|---|
Пазарна капитализация | 718M 5.4B |
|---|---|
Предишно отваряне | 29.53 |
Предишно затваряне | 29.22 |
Настроения в новините
By Acuity
34%
66%
87 / 342 Класиране в Healthcare
Legend Biotech Corp ADR Графика
Миналото представяне не гарантира бъдещи резултати.
Относно Legend Biotech Corp ADR
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation operates as a subsidiary of Genscript Biotech Corporation.